Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty

NCT00595426 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00595426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00595426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of YM150 in Subjects Undergoing Primary Elective Knee Arthroplasty
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
May 31, 2009
Enrollment
685 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

arthroplasty, replacement, knee